• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

体外生成模拟结直肠癌肿瘤免疫抑制环境的髓源性抑制细胞。

Ex vivo generation of myeloid-derived suppressor cells that model the tumor immunosuppressive environment in colorectal cancer.

作者信息

Dufait Inès, Schwarze Julia Katharina, Liechtenstein Therese, Leonard Wim, Jiang Heng, Escors David, De Ridder Mark, Breckpot Karine

机构信息

UZ Brussel, Department of Radiotherapy, Vrije Universiteit Brussel, Brussels, Belgium.

Laboratory of Molecular and Cellular Therapy, Vrije Universiteit Brussel, Brussels, Belgium.

出版信息

Oncotarget. 2015 May 20;6(14):12369-82. doi: 10.18632/oncotarget.3682.

DOI:10.18632/oncotarget.3682
PMID:25869209
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4494944/
Abstract

Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of cells that accumulate in tumor-bearing subjects and which strongly inhibit anti-cancer immune responses. To study the biology of MDSC in colorectal cancer (CRC), we cultured bone marrow cells in conditioned medium from CT26 cells, which are genetically modified to secrete high levels of granulocyte-macrophage colony-stimulating factor. This resulted in the generation of high numbers of CD11b(+) Ly6G(+) granulocytic and CD11b(+) Ly6C(+) monocytic MDSC, which closely resemble those found within the tumor but not the spleen of CT26 tumor-bearing mice. Such MDSC potently inhibited T-cell responses in vitro, a process that could be reversed upon blocking of arginase-1 or inducible nitric oxide synthase (iNOS). We confirmed that inhibition of arginase-1 or iNOS in vivo resulted in the stimulation of cytotoxic T-cell responses. A delay in tumor growth was observed upon functional repression of both enzymes. These data confirm the role of MDSC as inhibitors of T-cell-mediated immune responses in CRC. Moreover, MDSC differentiated in vitro from bone marrow cells using conditioned medium of GM-CSF-secreting CT26 cells, represent a valuable platform to study/identify drugs that counteract MDSC activities.

摘要

髓源性抑制细胞(MDSC)是一类异质性细胞群体,在荷瘤个体中积聚,并强烈抑制抗癌免疫反应。为了研究结直肠癌(CRC)中MDSC的生物学特性,我们在来自CT26细胞的条件培养基中培养骨髓细胞,CT26细胞经过基因改造可分泌高水平的粒细胞-巨噬细胞集落刺激因子。这导致产生了大量CD11b(+)Ly6G(+)粒细胞性和CD11b(+)Ly6C(+)单核细胞性MDSC,它们与CT26荷瘤小鼠肿瘤内而非脾脏中的MDSC非常相似。这种MDSC在体外强烈抑制T细胞反应,这一过程在阻断精氨酸酶-1或诱导型一氧化氮合酶(iNOS)后可逆转。我们证实,体内抑制精氨酸酶-1或iNOS会导致细胞毒性T细胞反应的刺激。在两种酶的功能受到抑制后,观察到肿瘤生长延迟。这些数据证实了MDSC作为CRC中T细胞介导的免疫反应抑制剂的作用。此外,使用分泌GM-CSF的CT26细胞的条件培养基在体外从骨髓细胞分化而来的MDSC,是研究/鉴定对抗MDSC活性药物的宝贵平台。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea89/4494944/e59f61e32e0e/oncotarget-06-12369-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea89/4494944/2464d0c79681/oncotarget-06-12369-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea89/4494944/8778306527ea/oncotarget-06-12369-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea89/4494944/cea1ac5253e4/oncotarget-06-12369-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea89/4494944/e59f61e32e0e/oncotarget-06-12369-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea89/4494944/2464d0c79681/oncotarget-06-12369-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea89/4494944/8778306527ea/oncotarget-06-12369-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea89/4494944/cea1ac5253e4/oncotarget-06-12369-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea89/4494944/e59f61e32e0e/oncotarget-06-12369-g004.jpg

相似文献

1
Ex vivo generation of myeloid-derived suppressor cells that model the tumor immunosuppressive environment in colorectal cancer.体外生成模拟结直肠癌肿瘤免疫抑制环境的髓源性抑制细胞。
Oncotarget. 2015 May 20;6(14):12369-82. doi: 10.18632/oncotarget.3682.
2
Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF.GM-CSF 决定髓源性抑制细胞亚群的免疫抑制强度的等级。
Eur J Immunol. 2010 Jan;40(1):22-35. doi: 10.1002/eji.200939903.
3
Critical Role of Mast Cells and Peroxisome Proliferator-Activated Receptor γ in the Induction of Myeloid-Derived Suppressor Cells by Marijuana Cannabidiol In Vivo.肥大细胞和过氧化物酶体增殖物激活受体γ在大麻二酚体内诱导髓源性抑制细胞中的关键作用
J Immunol. 2015 Jun 1;194(11):5211-22. doi: 10.4049/jimmunol.1401844. Epub 2015 Apr 27.
4
Tumor microenvironmental conversion of natural killer cells into myeloid-derived suppressor cells.肿瘤微环境将自然杀伤细胞转化为髓源性抑制细胞。
Cancer Res. 2013 Sep 15;73(18):5669-81. doi: 10.1158/0008-5472.CAN-13-0545. Epub 2013 Jul 18.
5
Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination.佐剂与髓源性抑制细胞:癌症治疗性疫苗接种中的敌人还是盟友?
Hum Vaccin Immunother. 2014;10(11):3251-60. doi: 10.4161/hv.29847.
6
Myeloid-derived suppressor cell functionality and interaction with Leishmania major parasites differ in C57BL/6 and BALB/c mice.髓源性抑制细胞的功能及其与利什曼原虫的相互作用在 C57BL/6 和 BALB/c 小鼠中存在差异。
Eur J Immunol. 2014 Nov;44(11):3295-306. doi: 10.1002/eji.201344335. Epub 2014 Sep 19.
7
Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13.骨髓髓源性抑制细胞(MDSCs)通过依赖精氨酸酶-1 的机制抑制移植物抗宿主病(GVHD),该机制受白细胞介素-13 上调。
Blood. 2010 Dec 16;116(25):5738-47. doi: 10.1182/blood-2010-06-287839. Epub 2010 Aug 31.
8
GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells.粒细胞-巨噬细胞集落刺激因子(GM-CSF)是主要的乳腺癌来源的可溶性因子之一,可诱导 CD11b-Gr1-骨髓祖细胞向髓源性抑制细胞分化。
Breast Cancer Res Treat. 2010 Aug;123(1):39-49. doi: 10.1007/s10549-009-0622-8. Epub 2009 Nov 8.
9
Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development.通过联合脂多糖和γ干扰素处理激活髓源性抑制细胞会损害树突状细胞的发育。
Eur J Immunol. 2009 Oct;39(10):2865-76. doi: 10.1002/eji.200939486.
10
Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events.肿瘤诱导的髓系来源抑制性细胞亚群对不同的 CD8+T 细胞激活事件发挥抑制或刺激作用。
Eur J Immunol. 2013 Nov;43(11):2930-42. doi: 10.1002/eji.201343349. Epub 2013 Aug 25.

引用本文的文献

1
Immunomodulatory function of cannabinoid receptor 2 and its agonist osteogenic growth peptide in health and cancer: a study in mice and humans.大麻素受体2及其激动剂成骨生长肽在健康与癌症中的免疫调节功能:一项小鼠和人类研究
Oncogene. 2025 Apr 30. doi: 10.1038/s41388-025-03399-9.
2
Telomeres, telomerase, and cancer: mechanisms, biomarkers, and therapeutics.端粒、端粒酶与癌症:作用机制、生物标志物及治疗方法
Exp Hematol Oncol. 2025 Jan 27;14(1):8. doi: 10.1186/s40164-025-00597-9.
3
Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition.

本文引用的文献

1
Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity.编码由干扰素-β(IFN-β)和转化生长因子-β受体II(TGF-β receptor II)胞外域组成的融合细胞因子的信使核糖核酸(mRNA)瘤内给药可增强抗肿瘤免疫力。
Oncotarget. 2014 Oct 30;5(20):10100-13. doi: 10.18632/oncotarget.2463.
2
iNOS expression in CD4+ T cells limits Treg induction by repressing TGFβ1: combined iNOS inhibition and Treg depletion unmask endogenous antitumor immunity.iNOS 在 CD4+T 细胞中的表达通过抑制 TGFβ1 来限制 Treg 的诱导:联合 iNOS 抑制和 Treg 耗竭揭示内源性抗肿瘤免疫。
Clin Cancer Res. 2014 Dec 15;20(24):6439-51. doi: 10.1158/1078-0432.CCR-13-3409. Epub 2014 Oct 2.
3
利用肿瘤微环境:通过调节上皮-间质转化实现靶向癌症治疗
J Hematol Oncol. 2025 Jan 13;18(1):6. doi: 10.1186/s13045-024-01634-6.
4
Enhancing Anti-PD-1 Immunotherapy by Targeting MDSCs via Hepatic Arterial Infusion in Breast Cancer Liver Metastases.通过肝动脉灌注靶向髓源性抑制细胞增强乳腺癌肝转移中的抗PD-1免疫疗法。
Cancers (Basel). 2024 Nov 3;16(21):3711. doi: 10.3390/cancers16213711.
5
Targeting amino acid-metabolizing enzymes for cancer immunotherapy.针对氨基酸代谢酶的癌症免疫疗法。
Front Immunol. 2024 Aug 14;15:1440269. doi: 10.3389/fimmu.2024.1440269. eCollection 2024.
6
MDSC expansion during HIV infection: regulators, ART and immune reconstitution.HIV 感染期间的 MDSC 扩增:调节因子、ART 和免疫重建。
Genes Immun. 2024 Jun;25(3):242-253. doi: 10.1038/s41435-024-00272-9. Epub 2024 Apr 11.
7
The Triple Crown: NO, CO, and HS in cancer cell biology.三重冠:癌症细胞生物学中的 NO、CO 和 HS。
Pharmacol Ther. 2023 Sep;249:108502. doi: 10.1016/j.pharmthera.2023.108502. Epub 2023 Jul 28.
8
The Cytokine Network in Colorectal Cancer: Implications for New Treatment Strategies.结直肠癌中的细胞因子网络:对新治疗策略的启示。
Cells. 2022 Dec 29;12(1):138. doi: 10.3390/cells12010138.
9
The emerging role of regulatory cell-based therapy in autoimmune disease.调节性细胞治疗在自身免疫性疾病中的新作用。
Front Immunol. 2022 Dec 14;13:1075813. doi: 10.3389/fimmu.2022.1075813. eCollection 2022.
10
Monocytic Myeloid-Derived Suppressor Cells from Tumor Tissue Are a Differentiated Cell with Limited Fate Plasticity.肿瘤组织中的单核细胞来源的髓系抑制细胞是一种命运可塑性有限的分化细胞。
Immunohorizons. 2022 Dec 1;6(12):790-806. doi: 10.4049/immunohorizons.2200079.
A highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in mice.
一种用于发现抗肿瘤靶点的高效肿瘤浸润性髓系来源抑制细胞分化系统,该系统无需在小鼠体内建立肿瘤模型。
Oncotarget. 2014 Sep 15;5(17):7843-57. doi: 10.18632/oncotarget.2279.
4
Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity.肿瘤衍生的前列腺素 E2 的抑制作用阻断了髓源性抑制细胞的诱导,并恢复了自然杀伤细胞的活性。
Clin Cancer Res. 2014 Aug 1;20(15):4096-106. doi: 10.1158/1078-0432.CCR-14-0635. Epub 2014 Jun 6.
5
GM-CSF Production by Tumor Cells Is Associated with Improved Survival in Colorectal Cancer.肿瘤细胞产生 GM-CSF 与结直肠癌患者的生存改善相关。
Clin Cancer Res. 2014 Jun 15;20(12):3094-106. doi: 10.1158/1078-0432.CCR-13-2774. Epub 2014 Apr 15.
6
A copper chelate selectively triggers apoptosis in myeloid-derived suppressor cells in a drug-resistant tumor model and enhances antitumor immune response.一种铜螯合物在耐药肿瘤模型中选择性地触发髓源性抑制细胞凋亡,并增强抗肿瘤免疫反应。
Immunopharmacol Immunotoxicol. 2014 Apr;36(2):165-75. doi: 10.3109/08923973.2014.897727. Epub 2014 Mar 10.
7
Depletion of myeloid-derived suppressor cells during interleukin-12 immunogene therapy does not confer a survival advantage in experimental malignant glioma.白细胞介素-12 免疫基因治疗期间髓源性抑制细胞耗竭并不能给实验性恶性脑胶质瘤带来生存优势。
Cancer Gene Ther. 2014 Jan;21(1):38-44. doi: 10.1038/cgt.2013.81. Epub 2014 Jan 17.
8
Advances in radiotherapy and targeted therapies for rectal cancer.直肠癌放射治疗和靶向治疗的进展。
World J Gastroenterol. 2014 Jan 7;20(1):1-5. doi: 10.3748/wjg.v20.i1.1.
9
DNA demethylating agent 5-azacytidine inhibits myeloid-derived suppressor cells induced by tumor growth and cyclophosphamide treatment.DNA 去甲基化剂 5-氮杂胞苷抑制肿瘤生长和环磷酰胺治疗诱导的髓源性抑制细胞。
J Leukoc Biol. 2014 May;95(5):743-753. doi: 10.1189/jlb.0813435. Epub 2014 Jan 3.
10
Assessing T-cell responses in anticancer immunotherapy: Dendritic cells or myeloid-derived suppressor cells?评估抗癌免疫疗法中的T细胞反应:树突状细胞还是髓源性抑制细胞?
Oncoimmunology. 2013 Oct 1;2(10):e26148. doi: 10.4161/onci.26148. Epub 2013 Sep 12.